Clinical Trials Browser

Phase 3 × Alpelisib × 90 days × Clear all

NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled 19 charts

Ovarian Neoplasms

NCT05038735 2026-06-02

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT04251533 2026-05-11

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT05646862 2026-05-06

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT04208178 2026-04-02

EPIK-B2

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer